Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LARIMAR THERAPEUTICS, INC.

(LRMR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
11.51(c) 12.63(c) 11.67(c) 11.3(c) 12.15 Last
110 673 212 960 129 261 101 354 31 770 Volume
-7.48% +9.73% -7.60% -3.17% +7.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -49,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,25x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -57,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,66x
Yield 2022 -
Capitalization 215 M 215 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 28
Free-Float 97,9%
More Financials
Company
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that is ineffective or no treatments... 
More about the company
All news about LARIMAR THERAPEUTICS, INC.
09/16LARIMAR THERAPEUTICS TO PARTICIPATE : Neuromuscular, Rare Diseases & Genetic Medicines Ev..
AQ
09/02LARIMAR THERAPEUTICS : to Present at the Morgan Stanley 19th Annual Global Healthcare Conf..
AQ
08/19LARIMAR THERAPEUTICS : Announces Upcoming Oral Presentation at the World Orphan Drug Congr..
AQ
08/12LARIMAR THERAPEUTICS : Reports Second Quarter 2021 Operating and Financial Results (Form 8..
PU
08/12LARIMAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/12LARIMAR THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, ..
AQ
08/12LARIMAR : Q2 Earnings Snapshot
AQ
08/12Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
GL
08/12Larimar Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Se..
CI
07/08LARIMAR THERAPEUTICS : to Present at the William Blair Biotech Focus Conference 2021
AQ
07/02INSIDER TRENDS : Insider Purchase Prolongs Larimar Therapeutics Positive Trend
MT
07/02INSIDER TRENDS : Insider Buy Scales Back 90-Day Trend of Sales at Larimar Therapeutics
MT
07/01LARIMAR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/14LARIMAR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/11Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference
GL
More news
News in other languages on LARIMAR THERAPEUTICS, INC.
2015Wall Street recule, plombée par l'énergie et la Fed
2015WALL STREET STOCK EXCHANGE : Wall Street termine dans le vert, 3ème semaine de hausse
2015WALL STREET STOCK EXCHANGE : Wall Street termine dans le vert, 3ème semaine de hausse
2015WALL STREET STOCK EXCHANGE : Wall Street termine dans le vert
2015Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on LARIMAR THERAPEUTICS, INC.
More recommendations
Chart LARIMAR THERAPEUTICS, INC.
Duration : Period :
Larimar Therapeutics, Inc. Technical Analysis Chart | LRMR | US5171251003 | MarketScreener
Technical analysis trends LARIMAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 12,15 $
Average target price 25,26 $
Spread / Average Target 108%
EPS Revisions
Managers and Directors
Carole S. Ben-Maimon President, Chief Executive Officer & Director
Michael Celano Chief Financial Officer
Joseph Truitt Chairman
Nancy M. Ruiz Chief Medical Officer
Noreen Scherer Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
LARIMAR THERAPEUTICS, INC.-43.25%200
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.36.63%69 407
REGENERON PHARMACEUTICALS33.91%67 262
VERTEX PHARMACEUTICALS-21.38%48 202